Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Scynexis, Inc.

Clinical trials sponsored by Scynexis, Inc., explained in plain language.

SCYNEXIS, Inc. SCYX NASDAQ

Biopharmaceutical company developing antifungal treatments.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

New pill could fight dangerous fungal infections

Disease control Terminated

This study tested a new oral antifungal drug, ibrexafungerp, for treating serious Candida infections in the blood or internal organs. 68 adults received an IV antifungal followed by either ibrexafungerp or standard oral fluconazole. The trial was stopped early, so the results are…

Phase: PHASE3 • Sponsor: Scynexis, Inc. • Aim: Disease control

Last updated Aug 12, 2026 00:00 UTC